110 related articles for article (PubMed ID: 21907283)
1. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
Chiang MC; Chern Y; Huang RN
Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.
Quintanilla RA; Jin YN; Fuenzalida K; Bronfman M; Johnson GVW
J Biol Chem; 2008 Sep; 283(37):25628-25637. PubMed ID: 18640979
[TBL] [Abstract][Full Text] [Related]
3. The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ.
Li X; Hernandez I; Koyuncu S; Kis B; Häggblad M; Lidemalm L; Abbas AA; Bendegúz S; Göblös A; Brautigam L; Lucas JJ; Carreras-Puigvert J; Hühn D; Pircs K; Vilchez D; Fernandez-Capetillo O
EBioMedicine; 2024 May; 103():105124. PubMed ID: 38701619
[TBL] [Abstract][Full Text] [Related]
4. Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.
Ju TC; Lin YS; Chern Y
Cell Mol Life Sci; 2012 Dec; 69(24):4107-20. PubMed ID: 22627493
[TBL] [Abstract][Full Text] [Related]
5. Modulation of nuclear REST by alternative splicing: a potential therapeutic target for Huntington's disease.
Chen GL; Ma Q; Goswami D; Shang J; Miller GM
J Cell Mol Med; 2017 Nov; 21(11):2974-2984. PubMed ID: 28524599
[TBL] [Abstract][Full Text] [Related]
6. Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.
Nadal X; Del Río C; Casano S; Palomares B; Ferreiro-Vera C; Navarrete C; Sánchez-Carnerero C; Cantarero I; Bellido ML; Meyer S; Morello G; Appendino G; Muñoz E
Br J Pharmacol; 2017 Dec; 174(23):4263-4276. PubMed ID: 28853159
[TBL] [Abstract][Full Text] [Related]
7. Role of TFEB in Huntington's Disease.
Ojalvo-Pacheco J; Yakhine-Diop SMS; Fuentes JM; Paredes-Barquero M; Niso-Santano M
Biology (Basel); 2024 Apr; 13(4):. PubMed ID: 38666850
[TBL] [Abstract][Full Text] [Related]
8. Mutant huntingtin fails to directly impair brain mitochondria.
Hamilton J; Brustovetsky T; Brustovetsky N
J Neurochem; 2019 Dec; 151(6):716-731. PubMed ID: 31418857
[TBL] [Abstract][Full Text] [Related]
9. miR-196a provides antioxidative neuroprotection via USP15/Nrf2 regulation in Huntington's disease.
Chan SC; Tung CW; Lin CW; Tung YS; Wu PM; Cheng PH; Chen CM; Yang SH
Free Radic Biol Med; 2023 Nov; 209(Pt 2):292-300. PubMed ID: 37907121
[TBL] [Abstract][Full Text] [Related]
10. Amendment of Altered Immune Response by Curcumin in Drosophila Model of Huntington's Disease.
Dhankhar J; Shrivastava A; Agrawal N
J Huntingtons Dis; 2023; 12(4):335-354. PubMed ID: 37781812
[TBL] [Abstract][Full Text] [Related]
11. Novel Metabolic Abnormalities in the Tricarboxylic Acid Cycle in Peripheral Cells From Huntington's Disease Patients.
Naseri NN; Bonica J; Xu H; Park LC; Arjomand J; Chen Z; Gibson GE
PLoS One; 2016; 11(9):e0160384. PubMed ID: 27611087
[TBL] [Abstract][Full Text] [Related]
12. Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington's Disease.
White A; McGlone A; Gomez-Pastor R
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009526
[TBL] [Abstract][Full Text] [Related]
13. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
[TBL] [Abstract][Full Text] [Related]
14. Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.
Singh J; Olle B; Suhail H; Felicella MM; Giri S
J Neurochem; 2016 Jul; 138(1):86-100. PubMed ID: 26849413
[TBL] [Abstract][Full Text] [Related]
15. Novel Therapeutic Targets and Drug Candidates for Modifying Disease Progression in Adrenoleukodystrophy.
Pujol A
Endocr Dev; 2016; 30():147-60. PubMed ID: 26684655
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
17. Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice.
Forss-Petter S; Werner H; Berger J; Lassmann H; Molzer B; Schwab MH; Bernheimer H; Zimmermann F; Nave KA
J Neurosci Res; 1997 Dec; 50(5):829-43. PubMed ID: 9418970
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial quality control in human health and disease.
Liu BH; Xu CZ; Liu Y; Lu ZL; Fu TL; Li GR; Deng Y; Luo GQ; Ding S; Li N; Geng Q
Mil Med Res; 2024 May; 11(1):32. PubMed ID: 38812059
[TBL] [Abstract][Full Text] [Related]
19. Vitamin B
Pradhan SS; Rao KR; Manjunath M; Saiswaroop R; Patnana DP; Phalguna KS; Choudhary B; Sivaramakrishnan V
3 Biotech; 2023 Mar; 13(3):96. PubMed ID: 36852176
[TBL] [Abstract][Full Text] [Related]
20. Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate.
Pizcueta P; Vergara C; Emanuele M; Vilalta A; Rodríguez-Pascau L; Martinell M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
